Nancy Lelicoff

Nancy Lelicoff possesses extensive experience in regulatory affairs, quality assurance, and clinical affairs within the life sciences sector. Currently serving as an Advisor for R&D, RA, and QA at NXgen Port since December 2020, and as a Board of Directors Member for Alternative Family Services, Nancy has held pivotal roles in several companies, including as EVP of Regulatory, Quality & Clinical Affairs at Sense Biodetection Ltd. from February 2022 to February 2023, following its acquisition by Sherlock Biosciences. Nancy's previous experience includes leadership positions at Agilent Technologies, Volcano Corporation, and Boston Scientific, among others. Nancy holds a Bachelor of Science in Engineering from the University of Arizona and a Master of Science in Engineering and Technical Management from West Coast University.